IP Verse

Once Daily Formulation Of Lacosamide - EP2645997

The patent EP2645997 was granted to UCB Pharma on Aug 10, 2022. The application was originally filed on Dec 1, 2011 under application number EP11791442A. The patent is currently recorded with a legal status of "Revoked".

EP2645997

UCB PHARMA
Application Number
EP11791442A
Filing Date
Dec 1, 2011
Status
Revoked
Sep 6, 2024
Grant Date
Aug 10, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMay 10, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (33) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0888289
DESCRIPTIONEP1243262
DESCRIPTIONEP1243263
DESCRIPTIONEP1541138
DESCRIPTIONEP1754476
DESCRIPTIONEP1920780
DESCRIPTIONEP1925314
DESCRIPTIONEP2035029
DESCRIPTIONEP2037965
DESCRIPTIONUS2006009384
DESCRIPTIONUS2011021482
DESCRIPTIONUS6133261
DESCRIPTIONWO2005053667
DESCRIPTIONWO2005092313
DESCRIPTIONWO2005099740
DESCRIPTIONWO2005110390
DESCRIPTIONWO2005120476
DESCRIPTIONWO2005120539
DESCRIPTIONWO2006000397
DESCRIPTIONWO2006021412
DESCRIPTIONWO2006079547
DESCRIPTIONWO2007144196
DESCRIPTIONWO2008000513
DESCRIPTIONWO2010148300
INTERNATIONAL-SEARCH-REPORTWO2008086492
INTERNATIONAL-SEARCH-REPORTWO2010060624
INTERNATIONAL-SEARCH-REPORTWO2011055385
OPPOSITIONUS2009143362
OPPOSITIONWO2007052125
OPPOSITIONWO2008086492
OPPOSITIONWO2009069089
OPPOSITIONWO2010060624
OPPOSITIONWO2011055385

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Note for Guidance on Modified Release Oral and Transdermal Dosage Forms: Section II (Pharmacokinetic and Clinical Evaluation)", EMEA COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP), (19990728), pages 1 - 12, EMEA COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP), (20181120), XP055525212
OPPOSITION- Anonymous, "Vimpat (lacosamide) Tablets and Injection", INTERNET CITATION, (20081001), INTERNET CITATION, URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf, (20121112), XP055043938
OPPOSITION- John H. Collett, "Chapter 23:: Dosage regimens", John H. Collett, Michael E. Aulton, [Pharmaceutics] Aulton's pharmaceutics : the design and manufacture of medicines, Churchill Livingstone Elsevier, (20070101), pages 324 - 334, ISBN 9780443101076, XP009556291
OPPOSITION- John H. Collett; R. C. Moreton, "Chapter 32: Modified-release peroral dosage forms", John H. Collett; R. C. Moreton, MICHAEL E. AULTON: "The design and manufacture of medicines, 3rd Edition", 2007, ISBN: 9780443101076, pages: 328, 486-487, 490-491, Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, CHURCHILL LIVINGSTONE ELSEVIER, (20070101), pages 483 - 499, ISBN 978-0-443-10107-6, XP009556289
OPPOSITION- Lucy Wan Sai Cheong, " Relationship Between Polymer Viscosity and Drug Release from a Matrix System", Pharmaceutical Research, (19921101), vol. 9, no. 11, pages 1510 - 1514, XP093164623
OPPOSITION- MICHAEL E. AULTON, "Passage: Modified-release peroral dosage forms", [Pharmaceutics] Aulton's pharmaceutics : the design and manufacture of medicines, CHURCHILL LIVINGSTONE ELSEVIER, (2007), pages 486 - 487, ISBN 978-0-443-10107-6
OPPOSITION- Xiaoling Lo, Rhaskara R. Jasti, "Chapter 5. Dissolution Controlled Drug Delivery Systems", Xiaoling Lo, Rhaskara R. Jasti, Xiaoling Lo, Rhaskara R. Jasti, Design of controlled release drug delivery systems, New York, McGraw Hill Chemical Engineering, (20060101), pages 139 - 172, doi:10.1036/0071417591, ISBN 0-07-141759-1, XP009556526
OPPOSITION- Xuan Ding, Adam WG Alani, Joseph R Robinson, "Chapter 47 Extended-Release and Targeted Drug Delivery Systems", Xuan Ding, Adam WG Alani, Joseph R Robinson, David Troy, Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & Wilkins, (20050101), pages 939 - 940, ISBN 0-7817-4673-6, XP009556118
OPPOSITION- Elinor Ben‐Menachem; Victor Biton; Dalius Jatuzis; Bassel Abou‐Khalil; Pamela Doty; G. David Rudd, "Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures", Epilepsia, Raven press LTD, New York , US, New York , US , (20070716), vol. 48, no. 7, doi:10.1111/j.1528-1167.2007.01188.x, ISSN 0013-9580, pages 1308 - 1317, XP071209783

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents